Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Vanda, despite FDA rejection, swats down another buyout bid from Cycle https://t.co/tDgym2esri
Today in Bloomberg Deals: The battle for Sanofi's Opella, Elliott seeks Southwest board vote and Lundbeck to buy Longboard Pharma https://t.co/MTOrWOhaoD
$VNDA Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group. Board Has Determined That Latest Proposal Is Not in the Best Interests of the Company or Stockholders https://t.co/eN98yN1lUZ
Cycle Pharma remains interested in acquiring Vanda Pharmaceuticals even after one of Vanda's drugs failed to receive regulatory approval. Cycle Pharma has maintained its takeover offer, but Vanda has confirmed the receipt of an unsolicited, economically identical, non-binding proposal from Cycle Group. Vanda's board has determined that the latest proposal is not in the best interests of the company or its stockholders.